Infectious Diseases Drug Delivery Systems

Shegokar, Ranjita, Pathak, Yashwant

  • 出版商: Springer
  • 出版日期: 2024-05-19
  • 售價: $5,710
  • 貴賓價: 9.5$5,425
  • 語言: 英文
  • 頁數: 439
  • 裝訂: Quality Paper - also called trade paper
  • ISBN: 3031205235
  • ISBN-13: 9783031205231
  • 海外代購書籍(需單獨結帳)

相關主題

商品描述

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future.

A total of four books are covered under the series of Infectious drug diseases.

- Malarial drug delivery systems

- Tubercular drug delivery systems

- Viral drug delivery systems

- Infectious disease drug delivery systems

Infectious diseases are the world's greatest killers that present one of the most significant health and security challenges. Humans have lived with emerging and re-emerging pathogens since before the documented history of civilization. The only determining fact today is - If the situation is "worse" or "better" than in past. The answer is probably "worse", may be due significant increase in human population, increased cross-continent mobility, imbalanced (stressed) life style, irregular food habits leading to compromised innate immunity and over or under practiced hygiene routine. When the incidence of such a disease in people increases over 20 years or threatens to increase, it is called an "emerging" disease, and a growing number have made watch lists andheadlines in nearly every country -like highly pathogenic H5N1 avian influenza, severe acute respiratory syndrome (SARS), Ebola virus, food- and waterborne illnesses, and a range of antimicrobial-resistant bacterial diseases TB. This book addresses current and new therapy developments in treating such infectious diseases, updates on finding new drugs, identification of innovative diagnostic methods, understanding of disease research models and clinical trials performances of new treatment modalities.

Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of infectious diseases and related research.

商品描述(中文翻譯)

失能調整生命年(DALY)是一種通用的衡量健康效應的指標,可用於成本效益分析,作為品質調整生命年(QALY)的替代方案。傳染病是導致DALY和QALY顯著損失的主要原因之一。人類傳染病是由細菌、真菌、病毒或寄生蟲等微生物引起的疾病。這些疾病中的大多數具有傳染性,對公共衛生構成威脅。傳染病致命的原因有很多,其中一個主要原因是隨著時間的推移產生的藥物抗藥性。與藥物抗藥性相關的突變與藥物外排增加、藥物或其靶標的修飾有關。每年,美國食品和藥物管理局(FDA)批准新藥治療傳染病。然而,傳染病無疑將繼續成為現在和未來對人類的永久和主要威脅。

《傳染性藥物疾病系列》共涵蓋四本書:
- 瘧疾藥物傳遞系統
- 結核病藥物傳遞系統
- 病毒性疾病藥物傳遞系統
- 傳染病藥物傳遞系統

傳染病是全球最致命的疾病,也是最重要的健康和安全挑戰之一。人類自文明有記錄以來就一直與新興和再現的病原體共存。今天唯一確定的事實是,情況是比過去更糟還是更好。答案可能是“更糟”,可能是由於人口顯著增加、跨洲流動增加、不平衡(壓力)的生活方式、不規律的飲食習慣導致免疫力受損以及過度或不足的衛生習慣。當某種疾病在人群中的發病率在20年內增加或有可能增加時,被稱為“新興”疾病,越來越多的疾病被列入監測名單,並成為幾乎每個國家的頭條新聞,如高致病性H5N1禽流感、嚴重急性呼吸道綜合症(SARS)、埃博拉病毒、食物和水傳播的疾病以及一系列抗藥性細菌疾病如結核病。本書介紹了治療這些傳染病的當前和新的治療進展,新藥的發現,創新診斷方法的確定,對疾病研究模型的理解以及新治療方法的臨床試驗表現。

從研究人員、學者、公共衛生機構到監管專家,各種廣泛的群體都可以從這些匯編的信息中受益,了解更多關於患者需求和傳染病及相關研究領域的當前研究進展。

作者簡介

Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. For the last many years she has been working with various multinational pharmaceutical companies in technical/R&D leadership roles. Currently, she serves as a Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited multiple trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received numerous prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Herareas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems (www.ranjitas.com).

Yashwant Pathak completed his Ph.D. in Pharmaceutical Technology from India and EMBA and MS Conflict Management from Sullivan University, USA. He is Associate Dean for Faculty Affairs College of Pharmacy, University of South Florida. Tampa, Florida. With extensive experience in academia and industry, he has over 150 research publications, abstracts, chapters and reviews, 7 books in Nanotechnology and drug delivery systems, 6 in Nutraceuticals and several books in cultural studies. His areas of research include drug delivery systems, nanotechnology applications for pharmaceutical and Nutraceuticals. He has traveled extensively over 80 countries to network scientific experts and is actively involved with many Pharmacy colleges in different countries.

作者簡介(中文翻譯)

Ranjita Shegokar擁有印度SNDT大學藥學技術博士學位,曾在德國柏林自由大學藥學、生物藥學和營養化妝品系進行博士後研究。多年來,她一直在各個跨國製藥公司擔任技術/研發領導職位。目前,她擔任德國Capnopharm GmbH的首席科學官(CSO)。她撰寫了多篇研究論文、專書章節,並在許多國內/國際會議上發表了她的研究成果。她在藥物傳遞和靶向領域申請了多項專利。此外,她還編輯了多本關於藥物納米技術和藥物傳遞方面的熱門書籍。她的研究成果獲得了多個國內外的重要獎項,其中包括最近獲得的德國創新獎2022。她的研究興趣包括高分子納米顆粒、納米晶體、脂質納米顆粒(SLNs/NLCs)、納米乳劑、癌症藥物靶向以及輔料在藥物傳遞系統中的作用(www.ranjitas.com)。

Yashwant Pathak在印度獲得藥學技術博士學位,並在美國蘇利文大學獲得EMBA和MS衝突管理學位。他是南佛羅里達大學藥學院教師事務副院長,位於佛羅里達州坦帕市。他在學術界和工業界擁有豐富的經驗,發表了150多篇研究論文、摘要、章節和評論,撰寫了7本有關納米技術和藥物傳遞系統的書籍,6本有關營養補充品的書籍,以及多本有關文化研究的書籍。他的研究領域包括藥物傳遞系統、藥物納米技術應用和營養補充品。他曾到訪80多個國家與科學專家建立聯繫,並積極參與不同國家的藥學院。